Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328556 | 0.84 | TDP1 (0.31) | TDP1TSHR | |
| SCHEMBL16327711 | 0.82 | ALDH1A1 (0.41) | TDP1TSHR | |
| SCHEMBL6891499 | 0.80 | — | — | |
| SCHEMBL602024 | 0.77 | TDP1 (0.35) | TDP1TSHR | |
| SCHEMBL6891504 | 0.77 | TDP1 (0.35) | TDP1TSHR | |
| SCHEMBL9341152 | 0.75 | HTT (0.33) | TSHRHTT | |
| SCHEMBL9792928 | 0.75 | — | — | |
| SCHEMBL19774819 | 0.73 | — | — | |
| SCHEMBL24943254 | 0.72 | TSHR (0.33) | TSHR | |
| SCHEMBL21902649 | 0.72 | TSHR (0.48) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486220-B2 | Method for the purification of ethylene cyanohydrin | EVONIK OPERATIONS GMBH (DE) | 2025-12-02 | — | — | US | disclosed |
| US-20240034715-A1 | A METHOD FOR THE PURIFICATION OF ETHYLENE CYANOHYDRIN | EVONIK OPERATIONS GMBH (DE) | 2024-02-01 | — | — | US | disclosed |
| EP-4073031-B1 | A METHOD FOR THE PURIFICATION OF ETHYLENE CYANOHYDRIN | EVONIK OPERATIONS GMBH (DE) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022122273-A1 | A METHOD FOR THE PURIFICATION OF ETHYLENE CYANOHYDRIN | EVONIK OPERATIONS GMBH (DE) | 2022-06-16 | — | — | WO | disclosed |
| US-10131908-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| US-8927513-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2551273-A1 | PHOSPHORYLATION REAGENT | The University of Tokyo (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20120322993-A1 | Phosphorylation Reagent | NIPPON SHINYAKU CO., LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011005860-A2 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-5256549-A | Biosynthesis using blocked monomers; followed by enzymatic hydrolysis | CHIRON CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | TDP1 514/4885TSHR 3336/4885HTT 3996/4885 |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | TDP1 518/4885TSHR 3344/4885HTT 3977/4885 |
| US-10131908-B2 | 5′ phosphate mimics | NSUN2, RNGTT, RNMT | TDP1 515/4885TSHR 3339/4885HTT 3971/4885 |
| US-20120322993-A1 | Phosphorylation Reagent | CSNK2A2, CSNK2A1, CSNK2B | TDP1 3038/4885TSHR 3733/4885HTT 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.